Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.59 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 4/20 | 0.44 |
| ▸ | CTSD | P07339 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5970284 | 1.00 | DPP4 (0.59) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL29452652 | 0.94 | DPP4 (0.54) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL31039944 | 0.93 | DPP4 (0.52) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL18797435 | 0.93 | DPP4 (0.52) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL29646209 | 0.90 | DPP4 (0.50) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL29974566 | 0.90 | DPP4 (0.50) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL29974881 | 0.90 | DPP4 (0.50) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL31721018 | 0.89 | BACE1 (0.53) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL5970526 | 0.89 | DPP4 (0.58) | DPP4DPP8DPP9ALOX15BLM | |
| SCHEMBL4388337 | 0.89 | DPP4 (0.58) | DPP4DPP8DPP9ALOX15BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | claimed |
| CN-118897023-B | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2025-03-25 | — | — | CN | claimed |
| CN-118897023-A | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2024-11-05 | — | — | CN | claimed |
| WO-2024216031-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2024-07-11 | — | — | US | claimed |
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | IMMUNOGEN INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4347661-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | ImmunoGen, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| US-20230391733-A1 | SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2023-12-07 | — | — | US | claimed |
| US-20150065460-A1 | Biomarkers Related to Insulin Resistance and Methods Using the Same | METABOLON, INC. | 2015-03-05 | — | — | US | claimed |
| EP-2546649-B1 | Biomarkers for fatty liver disease and methods using the same | METABOLON INC (US) | 2015-02-25 | — | — | EP | claimed |
| EP-2756095-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013039898-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-03-21 | — | — | WO | claimed |
| EP-2546649-A2 | Biomarkers for fatty liver disease and methods using the same | Metabolon Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| EP-2227689-B1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-20120122981-A1 | Biomarkers Related to Insulin Resistance and Methods using the Same | METABOLON, INC. | 2012-05-17 | — | — | US | claimed |
| EP-2414535-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | Metabolon Inc. (US) | 2012-02-08 | — | — | EP | claimed |
| US-20100279956-A1 | Biomarkers For Fatty Liver Disease And Methods Using The Same | METABOLON, INC. | 2010-11-04 | — | — | US | claimed |
| WO-2010114897-A1 | BIOMARKERS RELATED TO INSULIN RESISTANCE AND METHODS USING THE SAME | METABOLON, INC. (US) | 2010-10-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | DPP4 1262/4885DPP8 3390/4885DPP9 2149/4885 |
| US-20240165256-A1 | METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER | ADAM9, TMPRSS15, ADAM17 | DPP4 466/4885DPP8 346/4885DPP9 14/4885 |
| US-20240226312-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | FOLR1, FOLR2, FRS2 | DPP4 4488/4885DPP8 3928/4885DPP9 3873/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | DPP4 2235/4885DPP8 3838/4885DPP9 3056/4885 |
| US-20230391733-A1 | SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES | GABRA2, GABRA4, GABRA1 | DPP4 4517/4885DPP8 4668/4885DPP9 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.